The import of blood-grouping reagents to Saudi Arabia has exhibited significant fluctuations over the past decade. Starting at 43.749 million USD in 2013, it peaked in 2015 at 81.012 million USD before experiencing a dramatic drop to 29.129 million USD in 2018. The market stabilized from 2019 onwards, with a marginal average annual growth rate of 0.19% forecasted from 2024 to 2028. As of 2023, the imports stood at 37.955 million USD.

Year-on-year variations over the last two years have shown minimal changes, around 0.26% annually, reflecting a period of stabilization. The five-year compound annual growth rate (CAGR) leading up to 2023 was 5.44%, indicating a moderate recovery trajectory.

Future trends to watch for include:

Technological advancements in blood-grouping reagents that could impact import volumes
Policy changes in Saudi Arabia's healthcare system
Fluctuations in global market prices and suppliers
Potential shifts in healthcare priorities and budgets